10-Q: Butterfly Network Q3 Loss Widens on Inventory Write-Down

Butterfly Network reported a significant increase in net loss and a gross loss for Q3 2025, primarily due to a $17.4 million inventory write-down, despite a capital raise and revenue growth.

Summary

• Net loss for the three months ended September 30, 2025, nearly doubled to $34.0 million, compared to $16.9 million in the same period last year.
• The company recorded a gross loss of $3.8 million for Q3 2025, a significant decline from a gross profit of $12.2 million in Q3 2024.
• A non-recurring charge of $17.4 million for excess and obsolete inventory was recognized in Q3 2025, driven by technological advancements and changes in the product portfolio.
• Total revenue increased by 4.5% to $21.5 million for Q3 2025, with product revenue up 7.5% to $14.6 million, while software and other services revenue slightly decreased by 1.3% to $6.9 million.
• For the nine months ended September 30, 2025, total revenue grew 10.7% to $66.1 million, and net loss increased to $61.8 million from $54.4 million in the prior year.
• Net cash used in operating activities improved significantly, decreasing to $21.7 million for the nine months ended September 30, 2025, from $38.6 million in the prior year.
• The company completed a public offering on January 31, 2025, raising $81.0 million in net proceeds by issuing 27.6 million shares of Class A common stock.
• Cash and cash equivalents stood at $144.2 million as of September 30, 2025, up from $88.8 million at December 31, 2024.

Sentiment

Score: 4

Explanation: While the company achieved revenue growth and significantly improved its cash position through a capital raise, the substantial increase in net loss and the shift to a gross loss for the quarter, primarily due to a large inventory write-down, indicate significant operational challenges and a concerning impact on profitability. The slight decrease in software and services revenue mix, contrary to strategic goals, and ongoing litigation further temper positive sentiment.

Positives

• Total revenue increased by 4.5% for the quarter and 10.7% for the nine months ended September 30, 2025, demonstrating continued top-line growth.
• Product revenue saw a healthy increase of 7.5% for the quarter and 14.9% for the nine months, driven by higher average selling prices in international markets and increased sales volume in eCommerce and vet channels.
• Units fulfilled increased by 4.7% for the three months ended September 30, 2025, indicating growing adoption of devices.
• A public offering in January 2025 successfully raised $81.0 million in net proceeds, significantly boosting the company's cash and cash equivalents to $144.2 million.
• Net cash used in operating activities decreased by $16.9 million for the nine months ended September 30, 2025, reflecting improved operational cash management.
• The company has reduced its annual cash requirements by approximately $180 million since 2022, aiming for less than $50 million annually.
• Key leadership roles were strengthened with the promotion of Megan Carlson to SVP, Accounting and Finance Chief Accounting Officer, and the offer to Victor Ku as SVP, Chief Technology Officer.

Negatives

• Net loss for the three months ended September 30, 2025, nearly doubled to $34.0 million, compared to $16.9 million in the prior year.
• The company reported a gross loss of $3.8 million for Q3 2025, a substantial reversal from a gross profit of $12.2 million in Q3 2024.
• A non-recurring charge of $17.4 million for excess and obsolete inventory significantly impacted cost of product revenue and overall profitability.
• Software and other services revenue slightly decreased by 1.3% for the quarter, and the software and other services mix as a percentage of total revenue decreased to 32.3%, contrary to the company's long-term strategy to shift towards software.
• Legal costs increased by $1.9 million for the quarter and $2.1 million for the nine months due to ongoing litigation, contributing to higher 'Other' operating expenses.
• Net loss per common share increased to $(0.13) for the quarter from $(0.08) in the prior year.

Risks

• Growth depends on the ability to attract and retain customers.
• Business could be harmed if growth is not managed effectively.
• Current expectations and assumptions are subject to risks, estimates, and uncertainties.
• Business is subject to a variety of U.S. and foreign laws, which are subject to change and could adversely affect operations.
• The pricing of products and services, and reimbursement for medical procedures conducted using products and services, could impact financial performance.
• Ability to protect or enforce intellectual property rights is crucial for competitive advantage.
• Maintaining the listing of Class A common stock on the New York Stock Exchange is essential.
• Economic downturns and political and market conditions beyond control, including the imposition of tariffs, could adversely affect the business.
• Outcomes of ongoing litigation (class action and derivative lawsuits) are uncertain, and there is no assurance that insurance will be available or adequate to fund any potential settlement or judgment or litigation costs.
• Technological advancements in underlying components of devices and changes in the product portfolio could lead to further inventory obsolescence and write-downs.

Future Outlook

The company expects to continue investing in its business to grow revenue and anticipates its annual revenue mix will shift more toward software and other services over time. It also expects a higher proportion of sales in healthcare systems compared to eCommerce as healthcare system software offerings expand. Management plans substantial investments in product and software development, clinical, and regulatory capabilities. Existing cash and cash flows from operations are projected to be sufficient to meet liquidity, capital expenditure, and working capital requirements for at least the next 12 months.

Management Comments

• "We expect to continue to invest in our business in order to grow revenue."
• "Over time, as adoption of our devices increases through further market penetration and as practitioners in the Butterfly network continue to use our devices, we expect our annual revenue mix to shift more toward software and other services."
• "As we expand our healthcare system software offerings and develop relationships with larger healthcare systems, we continue to expect a higher proportion of our sales in healthcare systems compared to eCommerce."
• "Because the costs and associated expenses to deliver our SaaS offerings are less than the costs and associated expenses of manufacturing and selling our devices, we anticipate an improvement in profitability and margin expansion over time as our revenue mix shifts increasingly towards software and other services."
• "We plan to continue to make substantial investments in our product and software development, clinical, and regulatory capabilities."

Industry Context

Butterfly Network operates in the digital health and medical imaging industry, focusing on portable, semiconductor-based ultrasound technology. Its 'Ultrasound-on-Chip' solution aims to make medical imaging more accessible at the point-of-care, leveraging cloud-connected software and mobile applications. This aligns with broader industry trends towards decentralized healthcare, telehealth, and AI-powered diagnostics. The company's strategy to shift its revenue mix towards software and services reflects a common industry move to generate recurring revenue streams and improve profitability, although recent results show a temporary deviation from this trend.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks, making a direct assessment against industry standards challenging based solely on the provided information.
• The company's focus on portable, semiconductor-based ultrasound technology and cloud-connected software positions it within an innovative segment of the medical device industry, but without specific peer data, performance comparison is limited.

Management Changes

Corporate Governance

Legal Proceedings

• Rose v. Butterfly Network, Inc., et al.: A putative class action lawsuit filed on February 16, 2022, alleging false and misleading statements/omissions about post-Business Combination business and financial prospects. The company intends to vigorously defend against this action, but the outcome and potential loss are currently indeterminable.
• Koenig v. Todd M. Fruchterman, et al.: A stockholder derivative action filed on June 21, 2022, alleging violation of Section 14(a) of the Exchange Act, breach of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement, based on allegedly inadequate internal controls and misleading representations. The company intends to vigorously defend against this action, but the outcome and potential loss are currently indeterminable.
• Bhavsar v. Todd M. Fruchterman, et al.: A stockholder derivative action filed on November 28, 2023, with similar allegations to the Koenig action. The company intends to vigorously defend against this action, but the outcome and potential loss are currently indeterminable.

Related Party Transactions

• No specific related party transactions were explicitly disclosed beyond the general statement that the company is involved in litigation and legal matters from time to time, which have arisen in the normal course of business.

Stakeholder Impact

• **Shareholders**: Experienced dilution from the January 2025 public offering. The significant increase in net loss and gross loss for the quarter could negatively impact share value. Ongoing litigation creates uncertainty regarding potential financial liabilities.
• **Employees**: Key personnel received promotions and retention incentives. The company maintains a Flexible Paid Time Off policy and a 401(k) plan. A departing employee's RSUs were accelerated, indicating separation agreements.
• **Customers**: Continued product development, including the iQ3 probe, aims to enhance the value and accessibility of medical imaging solutions. Increased units fulfilled suggest growing customer base.
• **Suppliers/Partners**: The company has inventory purchase commitments with third-party manufacturers and delivers semiconductor chips to partners. Inventory write-downs could impact future purchasing strategies.
• **Creditors**: The successful capital raise significantly improved the company's cash position, enhancing its ability to meet contractual obligations for leases, technology licenses, and purchase commitments.

Next Steps

• Continue to invest in the business to grow revenue.
• Expand healthcare system software offerings and develop relationships with larger healthcare systems.
• Continue substantial investments in product and software development, clinical, and regulatory capabilities.
• Vigorously defend against ongoing class action and derivative lawsuits.
• Evaluate the impact of new accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-06) on financial statements and disclosures.

Key Dates

Recommendation

The significant deterioration in profitability, evidenced by a near-doubling of net loss and a shift to a gross loss for the quarter, is a major concern. The $17.4 million inventory write-down highlights operational inefficiencies or misjudgments in product lifecycle management. While the capital raise improved liquidity, it also caused dilution, and the underlying business performance remains weak. The slight decline in software and services revenue mix, contrary to the company's stated strategy for margin expansion, is also a negative indicator. Ongoing litigation adds further uncertainty and potential financial burden. Given these factors, a seasoned investor would likely view the current financial trajectory negatively.

Keywords

Digital Health, Ultrasound Technology, Medical Imaging, SEC Filing, 10-Q, Financial Results, Inventory Write-down, Net Loss, Revenue Growth, Capital Raise, Software as a Service, Healthcare Technology, Corporate Governance, Litigation, Executive Compensation